Xenetic Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on April 1, 2014. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the appointment of Darlene Deptula-Hicks as a member of the Board of Directors, effective April 1, 2014. Ms. Deptula-Hicks brings extensive experience as a senior financial executive in the life sciences sector, including prior roles as CFO at Microline Surgical, Inc. and ICAD, Inc.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies are disclosed in this document. The company notes that there is currently no employment agreement in place with the new director.
Key Facts for Investor Verification
- Appointment of Darlene Deptula-Hicks to the Board of Directors on April 1, 2014.
- New director has significant background in fundraising, M&A, and life sciences operations.
- No employment agreement exists with the new director at the time of filing.
- No financial data or operational results are included in this specific filing.